OverviewSuggest Edit

Roche (also known as F. Hoffmann-La Roch) is a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics. The Pharmaceutical segment provides drugs for cancer, viral infections, metabolic, central nervous system disorders, and inflammatory diseases. The Diagnostics segment supplies instruments and tests for disease screening and diagnosis in laboratories, at the point of care, and for patient self-management, as well as instruments, highly specific reagents, and test kits for use in the diverse research market with a focus on genomics and proteomics markets.
TypePublic
Founded1896
HQBasel, CH
Websiteroche.com

Latest Updates

Employees (est.) (Dec 2019)97,735(+4%)
Job Openings1,482
Revenue (FY, 2019)CHF63.8 B(+8%)
Share Price (Sept 2020)CHF334.3 (-1%)
Cybersecurity ratingBMore

Key People/Management at Roche

Severin Schwan

Severin Schwan

Chief Executive Officer and Board Member
William N. Anderson

William N. Anderson

CEO Roche Pharmaceuticals
Thomas Schinecker

Thomas Schinecker

CEO Roche Diagnostics
Matthew Sause

Matthew Sause

Chief Executive Officer, Roche Diagnostics North America
Alan Hippe

Alan Hippe

Chief Financial and IT Officer
Steve Guise

Steve Guise

CIO, Roche Pharmaceuticals
Show more

Roche Office Locations

Roche has offices in Basel, Risch-Rotkreuz, Rotkreuz ZG, Schlieren and in 127 other locations
Basel, CH (HQ)
124 Grenzacherstrasse
Basel, CH
Gartenstrasse 9
Basel, CH
Peter Merian-Weg 4/Haus 4
Risch-Rotkreuz, CH
Rischerstrasse
Rotkreuz ZG, CH
Forrenstrasse 2
Rotkreuz ZG, CH
Industriestrasse 7
Show all (166)

Roche Financials and Metrics

Roche Revenue

Embed Graph
View revenue for all periods
Roche's revenue was reported to be CHF63.75 b in FY, 2019 which is a 7.1% increase from the previous period.
CHF

Revenue (H1, 2020)

30.4b

Gross profit (H1, 2020)

22.6b

Gross profit margin (H1, 2020), %

74.4%

Net income (H1, 2020)

8.5b

EBIT (H1, 2020)

10.6b

Market capitalization (23-Sept-2020)

285.3b

Closing stock price (23-Sept-2020)

334.3

Cash (30-Jun-2020)

3.8b

EV

296.6b
Roche's current market capitalization is CHF285.3 b.
Annual
CHFFY, 2017FY, 2018FY, 2019

Revenue

55.7b59.5b63.8b

Revenue growth, %

6%7%7%

Cost of goods sold

18.2b17.3b18.4b

Gross profit

37.6b42.2b45.4b
Half Year
CHFH1, 2018H1, 2019H1, 2020

Revenue

29.5b31.8b30.4b

Cost of goods sold

8.0b8.7b7.8b

Gross profit

21.5b23.1b22.6b

Gross profit Margin, %

73%73%74%
Annual
CHFFY, 2017FY, 2018FY, 2019

Cash

4.7b6.7b6.1b

Accounts Receivable

9.6b9.8b10.4b

Inventories

7.4b6.6b6.1b

Current Assets

31.6b32.2b31.3b
Half Year
CHFH1, 2018H1, 2019H1, 2020

Cash

5.3b5.7b3.8b

Accounts Receivable

10.4b11.8b11.7b

Inventories

7.3b6.6b6.8b

Current Assets

29.6b32.3b27.7b
Annual
CHFFY, 2017FY, 2018FY, 2019

Net Income

8.8b10.9b14.1b

Depreciation and Amortization

3.9b3.6b4.3b

Cash From Operating Activities

18.0b20.0b22.4b

Purchases of PP&E

(3.5b)(4.0b)(3.5b)
Half Year
CHFH1, 2018H1, 2019H1, 2020

Net Income

7.5b8.9b8.9b

Depreciation and Amortization

1.8b2.1b2.2b

Cash From Operating Activities

8.1b8.1b7.1b

Purchases of PP&E

(1.7b)(1.5b)(1.6b)
CHFFY, 2017

EV/EBIT

17.5 x

EV/CFO

12.7 x

Revenue/Employee

594.7k

Debt/Equity

0.7 x

Debt/Assets

0.2 x

Financial Leverage

2.6 x

P/E Ratio

24.9
Show all financial metrics

Roche Operating Metrics

Roche's Patients was reported to be 63.2 m in FY, 2019.
FY, 2017FY, 2018FY, 2019

Patients

137.50 m127 m63.18 m

Patients Treated with Off-Patent Medicines

134.50 m124 m61.48 m

Patients Treated with Patent Medicines

3 m3 m1.70 m

Tests Conducted (Diagnostics Products)

19 b20 b21.40 b
Show all operating metrics

Roche Acquisitions / Subsidiaries

Company NameDateDeal Size
InflazomeSeptember 21, 2020$449 m
Stratos GenomicsMay 22, 2020
PromediorNovember 15, 2019$1.40 b
Spark TherapeuticsFebruary 25, 2019$4.80 b
Tusk TherapeuticsSeptember 28, 2018
Flatiron HealthFebruary 15, 2018$1.90 b
IgnytaDecember 22, 2017$1.70 b
ViewicsNovember 17, 2017
mySugrJune 30, 2017
ForSight LabsJanuary 10, 2017
Show more

Roche Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Roche Revenue Breakdown

Embed Graph

Roche revenue breakdown by business segment: 20.4% from Diagnostics and 79.6% from Pharmaceuticals

Roche revenue breakdown by geographic segment: 21.6% from Europe, 50.0% from North America, 21.6% from Asia and 6.9% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Roche Online and Social Media Presence

Embed Graph

Roche News and Updates

Goodwin Advises Inflazome on Sale to Roche to Continue Life Sciences M&A Success

The London Life Sciences team advised Inflazome on its acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) for an upfront consideration of €380 million. The shareholders of Inflazome, a Dublin-based biotech company leading in the development of inflammasome inhibitors, will also be eligible to receive…

Inflazome Announces Acquisition by Roche

Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain pre…

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020

Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO…

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adu…

Shares of Roche gain as it says arthritis drug can lessen need for ventilators in COVID-19 patients

Shares of Roche Holding AG gained 1.9% in premarket trading on Friday after the drug maker said hospitalized COVID-19 patients taking rheumatoid arthritis drug Actemra were less likely to need mechanical ventilation than those receiving placebo. The Phase 3, randomized, double-blind, placebo-contro…
Show more

Roche Frequently Asked Questions

  • When was Roche founded?

    Roche was founded in 1896.

  • Who are Roche key executives?

    Roche's key executives are Severin Schwan, William N. Anderson and Thomas Schinecker.

  • How many employees does Roche have?

    Roche has 97,735 employees.

  • What is Roche revenue?

    Latest Roche annual revenue is CHF63.8 b.

  • What is Roche revenue per employee?

    Latest Roche revenue per employee is CHF652.3 k.

  • Who are Roche competitors?

    Competitors of Roche include Amgen, Johnson & Johnson and Bayer.

  • Where is Roche headquarters?

    Roche headquarters is located at 124 Grenzacherstrasse, Basel.

  • Where are Roche offices?

    Roche has offices in Basel, Risch-Rotkreuz, Rotkreuz ZG, Schlieren and in 127 other locations.

  • How many offices does Roche have?

    Roche has 166 offices.